AR124286A1 - Proteínas de unión a il-7 y su uso en tratamientos médicos - Google Patents
Proteínas de unión a il-7 y su uso en tratamientos médicosInfo
- Publication number
- AR124286A1 AR124286A1 ARP210103301A ARP210103301A AR124286A1 AR 124286 A1 AR124286 A1 AR 124286A1 AR P210103301 A ARP210103301 A AR P210103301A AR P210103301 A ARP210103301 A AR P210103301A AR 124286 A1 AR124286 A1 AR 124286A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- set forth
- binding
- binding protein
- binding proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
En el presente documento se proporcionan proteínas de unión a interleucina 7 (IL-7), composiciones farmacéuticas y su uso en el tratamiento o prevención de una enfermedad o afección. Reivindicación 1: Una proteína de unión a IL-7 que se une a uno o más residuos de aminoácidos dentro de la secuencia de aminoácidos establecida en la SEQ ID Nº 12 de IL-7 humana. Reivindicación 4: Una proteína de unión a IL-7 caracterizada porque se une a IL-7 humana adyacente a un sitio de unión a IL-7Ra, con una KD de aproximadamente 100 nM o menos medida por ensayo de resonancia de plasmón de superficie. Reivindicación 7: Una proteína de unión a IL-7 caracterizada porque comprende CDRH1 como se establece en la SEQ ID Nº 6, CDRH2 como se indica en la SEQ ID Nº 7, CDRH3 como se indica en la SEQ ID Nº 8, CDRL1 como se indica en la SEQ ID Nº 9, CDRL2 como se establece en la SEQ ID Nº 10 y CDRL3 como se establece en la SEQ ID Nº 11. Reivindicación 27: Una composición farmacéutica, caracterizada porque comprende un transportador o excipiente farmacéuticamente aceptable y una proteína de unión a IL-7 que exhibe unión para IL-7 en un epítopo que comprende al menos 5 aminoácidos contiguos de una secuencia establecida en la SEQ ID Nº 12 o la SEQ ID Nº 16.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063120564P | 2020-12-02 | 2020-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124286A1 true AR124286A1 (es) | 2023-03-15 |
Family
ID=78844686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103301A AR124286A1 (es) | 2020-12-02 | 2021-11-30 | Proteínas de unión a il-7 y su uso en tratamientos médicos |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11802150B2 (es) |
| EP (1) | EP4255928A1 (es) |
| JP (1) | JP2023551935A (es) |
| KR (1) | KR20230098288A (es) |
| CN (1) | CN116547002A (es) |
| AR (1) | AR124286A1 (es) |
| AU (1) | AU2021391493B2 (es) |
| CA (1) | CA3199648A1 (es) |
| CL (1) | CL2023001556A1 (es) |
| CO (1) | CO2023007851A2 (es) |
| IL (1) | IL303134A (es) |
| MX (1) | MX2023006294A (es) |
| PH (1) | PH12023551170A1 (es) |
| TW (1) | TWI821804B (es) |
| WO (1) | WO2022117526A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR129445A1 (es) * | 2022-05-27 | 2024-08-28 | Glaxosmithkline Ip Dev Ltd | USO DE PROTEÍNAS DE UNIÓN A TNF-a Y PROTEÍNAS DE UNIÓN A IL-7 EN EL TRATAMIENTO MÉDICO |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| MXPA04001072A (es) | 2001-08-03 | 2005-02-17 | Glycart Biotechnology Ag | Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada. |
| ES2562177T3 (es) | 2002-09-27 | 2016-03-02 | Xencor Inc. | Variantes de Fc optimizadas y métodos para su generación |
| EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| CA2573745A1 (en) | 2004-07-21 | 2007-01-12 | Glycofi, Inc. | Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| HRP20161542T1 (hr) * | 2009-11-30 | 2016-12-30 | Janssen Biotech, Inc. | MUTIRANA Fc ANTITIJELA SA UKLONJENOM EFEKTORSKOM FUNKCIJOM |
-
2021
- 2021-11-30 JP JP2023533733A patent/JP2023551935A/ja active Pending
- 2021-11-30 CA CA3199648A patent/CA3199648A1/en active Pending
- 2021-11-30 KR KR1020237018159A patent/KR20230098288A/ko active Pending
- 2021-11-30 AU AU2021391493A patent/AU2021391493B2/en active Active
- 2021-11-30 CN CN202180081029.5A patent/CN116547002A/zh active Pending
- 2021-11-30 MX MX2023006294A patent/MX2023006294A/es unknown
- 2021-11-30 AR ARP210103301A patent/AR124286A1/es unknown
- 2021-11-30 IL IL303134A patent/IL303134A/en unknown
- 2021-11-30 EP EP21823820.2A patent/EP4255928A1/en active Pending
- 2021-11-30 WO PCT/EP2021/083465 patent/WO2022117526A1/en not_active Ceased
- 2021-11-30 US US17/538,431 patent/US11802150B2/en active Active
- 2021-11-30 TW TW110144544A patent/TWI821804B/zh active
- 2021-11-30 PH PH1/2023/551170A patent/PH12023551170A1/en unknown
-
2023
- 2023-05-31 CL CL2023001556A patent/CL2023001556A1/es unknown
- 2023-06-15 CO CONC2023/0007851A patent/CO2023007851A2/es unknown
- 2023-09-05 US US18/460,944 patent/US12122828B2/en active Active
-
2024
- 2024-09-03 US US18/823,000 patent/US20240425581A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI821804B (zh) | 2023-11-11 |
| US12122828B2 (en) | 2024-10-22 |
| CL2023001556A1 (es) | 2023-11-10 |
| US20240025988A1 (en) | 2024-01-25 |
| US11802150B2 (en) | 2023-10-31 |
| JP2023551935A (ja) | 2023-12-13 |
| WO2022117526A1 (en) | 2022-06-09 |
| CO2023007851A2 (es) | 2023-06-30 |
| US20220169717A1 (en) | 2022-06-02 |
| TW202237183A (zh) | 2022-10-01 |
| AU2021391493A1 (en) | 2023-06-08 |
| MX2023006294A (es) | 2023-06-13 |
| AU2021391493B2 (en) | 2025-10-30 |
| US20240425581A1 (en) | 2024-12-26 |
| CA3199648A1 (en) | 2022-06-09 |
| IL303134A (en) | 2023-07-01 |
| EP4255928A1 (en) | 2023-10-11 |
| KR20230098288A (ko) | 2023-07-03 |
| AU2021391493A9 (en) | 2024-05-23 |
| CN116547002A (zh) | 2023-08-04 |
| PH12023551170A1 (en) | 2024-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| AR127344A2 (es) | Conjugados anticuerpo-fármaco que comprenden agonistas de sting | |
| AR081556A1 (es) | Proteinas de union al antigeno humanizadas | |
| JP2020518599A5 (es) | ||
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) | |
| HRP20250666T1 (hr) | Anti-pro/latentna miostatinska protutijela i njihove uporabe | |
| JP2020500538A5 (es) | ||
| AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
| IL311145B2 (en) | Antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| FI4045533T3 (fi) | Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2) | |
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| JP2009511480A5 (es) | ||
| AR073770A1 (es) | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden | |
| RU2012156938A (ru) | Антитела против gdf8 человека | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| JP2015508762A5 (es) | ||
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| JP2014524748A5 (es) | ||
| RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
| AR103896A1 (es) | Conjugados de fármacos de anticuerpos (adc) anti-proteínas flt3 | |
| AR086579A1 (es) | Proteinas de union a antigeno | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| RU2020112280A (ru) | Конъюгаты анти-egfr антитело-лекарственное средство (adc) и их применение | |
| JP2023015301A5 (es) |